



Building partnerships between research and industry

Location:

Instituto de Medicina Molecular, João Lobo Antunes, Lisbon, Portugal

iMM Summit is a networking event that wants to match scientific and research capabilities with market needs. Industry will have the opportunity to learn more about the exciting science performed at iMM, as well as its preclinical and clinical research capacity. The iMM research community will be exposed to market trends and partnering opportunities offered by industry. During two days (November 16-17, 2018) iMM scientists and entrepreneurs, high-level industry representatives and policy makers will meet to **share ideas and shape the future of healthcare.**

Day 1: November 16, 2018

Room 58

14:00	Registration & Welcome Drink
14:30	iMM Institutional Presentation
15:00	<i>Bayer: Opportunities between Academia and Industry</i>
16:00	<i>AICEP: Investment Opportunities in Portugal</i>
16:30	<i>GammaDelta Therapeutics & Lymphact: iMM Start-up Success Case</i>
17:00	Networking cocktail and visit to iMM

Day 2: November 17, 2018

9:30	iMM Facility: Biobank Room 58		Networking rooms for F2F meetings
9:45	iMM Facility: Clinical Research Center - CIC Room 58		
	<u>Session 1 (Area A & B)</u> Room 58	<u>Session 2 (Area C & D)</u> Room 57	
10:00	Chemical Biology & Pharmaceutical Biotechnology	Lymphocyte Regulation	
10:20	Signaling in Cancer	Rheumatology Research	
10:40	Translational Oncobiology	Human Immunodeficiency & Immune Reconstitution	
11:00	Coffee Break		
11:40	Computational Biology	Biology of Parasitism	
12:00	Patient-derived models of brain metastases - a tool for translational medicine	Biology and Physiology of Malaria	
12:20	Neurobiology of Ageing & Disease	Plasmodium Infection & Anti-malarial Interventions	
12:40	Mitochondria Biology & Neurodegeneration	Physical Biochemistry of Drugs and Targets	
13:00	Lunch		
14:40	Room 58 Biogen		
15:00	AstraZeneca		
15:20	Janssen		
15:40	Healthtech TAB		
16:00	MSD		
16:20	Novartis		
16h40	Pfizer		
17h00	Farewell drink		

Area A: Oncology and Immuno-oncology; Area B: Neurosciences (CNS); Area C: Infectious Diseases and Vaccines; Area D: Autoimmunity and Inflammation.

Exhibition Area:



GenoMed is a spin-off company of iMM Lisboa created in 2004. The mission of **GenoMed is to provide cutting-edge technology transfer services relevant for medical applications**. Currently, GenoMed offers over **100 different tests that are used in diagnosis, prognosis and therapeutic follow up**. GenoMed acts in 3 main medical areas: Oncology, Infectious Diseases, Genetic Diseases and Pharmacogenetics.



The mission of RoPlaVac is to **develop medical solutions against malaria, one of the most prevalent diseases worldwide**. Malaria is caused by *Plasmodium* parasites, injected into their mammalian host as sporozoites, through the bite of an infected mosquito. Currently, RoPlaVac is engaged in three main endeavors: **Vaccination, Plasmodium sporozoite cryopreservation and In vitro Plasmodium sporozoite production**.



TechnoPhage is an innovative biopharmaceutical company engaged in the R&D of new molecules - chemical and biological - in diverse therapeutic areas, such as **infection, inflammation & immunology, neurology and metabolic disorders**. TechnoPhage's strategy is based on developing new therapeutics in early phases of R&D, with a view to then enters into collaboration deals for pre-clinical and/or clinical development.



DART Diagnostics was created to improve diagnostics, bringing the benefits of recent nanomedicine discoveries to industrial pathogen detection. DART's technology can be integrated into classical immunoassays, massively improving them and allowing high sensitivity and early detection. Therefore, pathogens can be identified at low concentrations before their spread and/or, in the case of food industry applications, before food recalls are needed.

CLARIFY ANALYTICAL

Clarify Analytical is an innovative service providing start-up committed to develop state-of-the-art analytical based methodologies (e.g. chromatographic, mass spectrometric and nuclear magnetic resonance) that allow the quantification and characterization of any type of biological molecules. The mission of Clarify Analytical is to take advantage of the capabilities of these analytical techniques to offer innovative services and develop new products in the areas of biotechnology and Healthcare.

Getting to iMM



Participants



John Butler

Vice President External Innovation
& Alliance Management and
Business Development



GAMMADELTA
THERAPEUTICS

Raj Mehta

Director of Intellectual Property, Alliance
Management & Business Development



Pedro Marques

External Affairs Director

Cláudia Duarte

Associate Director - Clinical Operations



Cátia Cantante

Medical Science Liaison -
Biosimilars



Carla Fernandes

Medical and Regulatory Affairs
Director

Filipa Bernardo

Data Generation Manager



José Antunes

Medical Director, New Venture Lead for
Portugal

Ana Filipa Guedes

Open Innovation



Roberto Abi Rached

Medical Director



Echard Schwenner

Expert

Rui Sousa

Program Manager,
Management Unit



José Aleixo Dias

Medical Director

Susana Marques

Senior Director Vaccines Western Europe

Ana Faber

Senior Medical Advisor Oncology

Isabel Freitas

Senior Medical Advisor Inflammation

Pedro Branquinho

Senior Medical Advisor Rare Diseases



Luis Laranjeira

Medical Director

Ana Sofia Soares

Medical Liaison

Eduardo Ferreira

Autoimmune Senior Brand

Manager



Miguel Sanches

Medical Director



Ana Rita Cravo

Medical Manager - Rheumatology

Marco Cardeira

Business Unit Manager

João Coelho Marques

Business Technology Manager



Joana Ogando

Business Development
Manager



GlaxoSmithKline

Paulo Diniz

Medical Liaison



Germàn Ha

BD and Regional Manager -
Spain, Portugal
Europe Business and Sales
Division



Pedro Lopes

Medical Director



João Galrito

General Manager



aicep Portugal Global

Miguel Fontoura
Commercial Director
Renata Gomes
Health Specialist



Gonçalo Amorim
Executive Director
Sofia Fernandes
Head of Marketing & Projects



Patricia Calado
National Contact Point for Horizon 2020 -
Health and IMI

Portugal
Ventures

Nuno Afonso
Investment Manager

newangle

Margarida Bjanca